Logo

An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

  1. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  2. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  3. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  4. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  5. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  6. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  7. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  8. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  9. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  10. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  11. Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. lvalor.hgugm@salud.madrid.org

CER10156 Submission on line
Full Papers

Rheumatology Article

 

Abstract

OBJECTIVES:
The aim of this study was to investigate the relationship between serum infliximab (IFX) levels and changes of RF and ACPA levels in patients with rheumatoid arthritis (RA).
METHODS:
Enzyme-linked immunosorbent assays (ELISA) [Promonitor® IFX R1 (version 2) (Progenika Biopharma, Spain)] were used to measure drug levels and antidrug-antibodies (ADAb) in IFX RA-treated patients (n=19). Disease activity was assessed using DAS28. IgM rheumatoid factor (RF) and IgM, IgA and IgG anti-cyclic citrullinated peptide (ACPA) were determined through ELISA.
RESULTS:
A significant decrease in RF (p=0.01), ACPA IgG (p=0.007), IgM (p=0.01) and IgA (p=0.03) was observed in patients presenting adequate levels of serum IFX. No significant changes to RF or ACPA were observed in patients with undetectable IFX.
CONCLUSIONS:
Data from this study support the hypothesis that the anti-TNF antagonist IFX downregulates autoantibody levels in RA patients when IFX levels are detectable. Larger-scale studies need to be performed to establish RF and ACPA presence as therapeutic response predictive factors.

PMID: 28850020 [PubMed]

Received: 07/12/2016 - Accepted : 24/05/2017 - In Press: 28/08/2017